0.100
0.00 (0.00%)
| Previous Close | 0.100 |
| Open | 0.190 |
| Volume | 31,864 |
| 52 Weeks Range |
| Profit Margin | -38.34% |
| Operating Margin (TTM) | -64.69% |
| Diluted EPS (TTM) | -1.30 |
| Quarterly Revenue Growth (YOY) | 34.00% |
| Total Debt/Equity (MRQ) | 13.20% |
| Current Ratio (MRQ) | 1.88 |
| Operating Cash Flow (TTM) | -18.91 M |
| Levered Free Cash Flow (TTM) | -17.96 M |
| Return on Assets (TTM) | -40.24% |
| Return on Equity (TTM) | -149.41% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bearish | Mixed | |
| Stock | Biofrontera Inc. Warrants | - | - |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | NA |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Average | -0.67 |
|
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |